Kyowa Hakko Kirin's first therapeutic biologic product, Poteligeo (mogamulizumab), has received a reimbursement price in Japan, clearing the way for its first launch worldwide in this market later this month.
The chemokine [C-C motif] receptor 4-targeting antibody was formally approved in late March for the orphan indication of relapsed/refractory CCR4-positive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?